Flurpiridaz f-18 - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for flurpiridaz f-18 and what is the scope of patent protection?
Flurpiridaz f-18
is the generic ingredient in one branded drug marketed by Ge Hlthcare and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.Flurpiridaz f-18 has one hundred and twenty-one patent family members in twenty-three countries.
One supplier is listed for this compound.
Summary for flurpiridaz f-18
| International Patents: | 121 |
| US Patents: | 7 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 5 |
| Patent Applications: | 92 |
| What excipients (inactive ingredients) are in flurpiridaz f-18? | flurpiridaz f-18 excipients list |
| DailyMed Link: | flurpiridaz f-18 at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for flurpiridaz f-18
Generic Entry Date for flurpiridaz f-18*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for flurpiridaz f-18
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Akiva Mintz | PHASE2 |
| GE Healthcare | Phase 2 |
| Pharmaceutical Product Development, LLC | Phase 3 |
Pharmacology for flurpiridaz f-18
| Drug Class | Radioactive Diagnostic Agent |
| Mechanism of Action | Positron Emitting Activity |
US Patents and Regulatory Information for flurpiridaz f-18
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Hlthcare | FLYRCADO | flurpiridaz f-18 | SOLUTION;INTRAVENOUS | 215168-001 | Sep 27, 2024 | RX | Yes | Yes | 8,226,929 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ge Hlthcare | FLYRCADO | flurpiridaz f-18 | SOLUTION;INTRAVENOUS | 215168-001 | Sep 27, 2024 | RX | Yes | Yes | 9,687,571 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Ge Hlthcare | FLYRCADO | flurpiridaz f-18 | SOLUTION;INTRAVENOUS | 215168-001 | Sep 27, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ge Hlthcare | FLYRCADO | flurpiridaz f-18 | SOLUTION;INTRAVENOUS | 215168-001 | Sep 27, 2024 | RX | Yes | Yes | 9,161,997 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for flurpiridaz f-18
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ge Hlthcare | FLYRCADO | flurpiridaz f-18 | SOLUTION;INTRAVENOUS | 215168-001 | Sep 27, 2024 | 9,161,997 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for flurpiridaz f-18
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 5417578 | ⤷ Start Trial | |
| Japan | 6254126 | ⤷ Start Trial | |
| Taiwan | 201741288 | ⤷ Start Trial | |
| South Africa | 200606429 | Contrast agents for myocardial perfusion imaging | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch